This research is being conducted to understand your opinion on a proposed cough syrup formulation by Pfizer. As you are aware, Doctors across specialties prescribe various cough syrups variants from Pfizer Portfolio viz. Corex Dx, Corex LS, Corex T, and Broncorex .
Further, to strengthen the portfolio and to provide physicians an additional option for the management of dry cough with congestion relief benefit, Pfizer is planning to launch a new extension /SKU. The Concept: The proposed new formulation will be a combination of chlorpheniramine maleate, dextromethorphan, and phenylephrine. Composition: Chlorpheniramine maleate + dextromethorphan + phenylephrine Product Formulation: Cough syrup You confirm that you have understood the description of this online survey conducted by Docplexus Online Services Private Limited (“Docplexus”) for its client Pfizer Limited, India (“Pfizer”) and…
